News Releases

Date Title and Summary Additional Formats
Toggle Summary HTG Molecular Diagnostics to Present at the Canaccord Genuity Growth Conference
TUCSON, Ariz. , July 30, 2015 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics , Inc. (Nasdaq:HTGM), a provider of instruments and reagents for molecular profiling applications, today announced that its management will be presenting at the Canaccord Genuity Growth Conference on Thursday, August 13,
View HTML
Toggle Summary HTG Molecular Diagnostics to Hold 2015 Second Quarter Financial Results Conference Call on August 6
TUCSON, Ariz. , July 27, 2015 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics , Inc. (Nasdaq:HTGM), a provider of instruments and reagents for molecular profiling applications, today announced that the Company will release 2015 second quarter financial results after market close on Thursday, August
View HTML
Toggle Summary HTG Molecular Diagnostics Achieves ISO 13485:2003 Recertification
TUCSON, Ariz. , July 23, 2015 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq:HTGM), a provider of instruments and reagents for molecular profiling applications, today announced that its has again achieved ISO 13485:2003 certification for the design, manufacture, and distribution of
View HTML
Toggle Summary HTG Molecular Diagnostics Added to Russell Microcap Index
TUCSON, Ariz. , June 29, 2015 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq:HTGM), a provider of instruments and reagents for molecular profiling applications, was added to the Russell Microcap® Index following the conclusion of the Russell indexes annual reconstitution on June 26,
View HTML
Toggle Summary HTG Molecular Diagnostics to Present at the JMP Securities Life Sciences Conference
TUCSON, Ariz., June 9, 2015 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics , Inc. (Nasdaq: HTGM ), a provider of instruments and reagents for molecular profiling applications, today announced that its management will be presenting at the JMP Securities Life Sciences Conference on Tuesday, June 23,
View HTML
Toggle Summary HTG Molecular Diagnostics Reports First Quarter 2015 Results
TUCSON, Ariz. , June 1, 2015 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics , Inc. (Nasdaq:HTGM), a provider of instruments and reagents for molecular profiling applications, today reported financial results for the three months ended March 31, 2015 . Recent Accomplishments & Highlights: Completed
View HTML
Toggle Summary HTG and MD Anderson Cancer Center Enter Into a Sponsored Research Agreement to Investigate New Molecular Diagnostics for Lung Cancer Using HTG's Next-Generation Sequencing Solution for Gene Expression
TUCSON, Ariz. , June 1, 2015 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq:HTGM), a provider of instruments and reagents for molecular profiling applications and The University of Texas MD Anderson Cancer Center have entered into a 2-year Sponsored Research Agreement to support
View HTML
Toggle Summary HTG Molecular Diagnostics to Hold 2015 First Quarter Financial Results Conference Call on June 1
TUCSON, Ariz. , May 26, 2015 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics , Inc. (Nasdaq:HTGM), a provider of instruments and reagents for molecular profiling applications, today announced that the Company will release 2015 first quarter financial results after market close on Monday, June 1, 2015
View HTML
Toggle Summary HTG Molecular Diagnostics Announces Pricing of Initial Public Offering
TUCSON, Ariz. , May 6, 2015 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. , a provider of instruments and reagents for molecular profiling applications, today announced the pricing of its initial public offering of 3,570,000 shares of its common stock at an initial public offering price of
View HTML
Toggle Summary HTG Launches a New Highly Multiplexed Profiling Panel Automated on the HTG EdgeSeq System
TUCSON, Ariz., Feb. 10, 2015 (GLOBE NEWSWIRE) -- Today  HTG Molecular Diagnostics , Inc. announced the availability of the HTG EdgeSeq Oncology Biomarker panel for profiling the expression of over 2,500 oncology related biomarkers. Automated on the HTG EdgeSeq system, HTG EdgeSeq Oncology
View HTML